ARL15 Activators
ARL15 activators are a selection of chemical compounds that could potentially enhance the functional activity of ARL15, a GTP-binding protein involved in vesicle transport, lipid metabolism, and signal transduction. Compounds like GTPγS are crucial as they can stabilize ARL15 in its active, GTP-bound state, thereby potentially enhancing its GTPase activity. Farnesyltransferase inhibitors like Tipifarnib and geranylgeranyltransferase inhibitors like GGTI-298 target post-translational modifications that are essential for the proper functioning and localization of proteins like ARL15, thereby potentially influencing its role in cellular signaling and vesicle transport.
Statins, including Atorvastatin, Lovastatin, and Simvastatin, along with other lipid-lowering agents like Clofibrate and Niacin, are included due to their roles in modulating lipid metabolism pathways. These compounds could potentially enhance the role of ARL15 in regulating lipid metabolic processes. Brefeldin A and Phenylarsine Oxide, known for their effects on disrupting vesicular trafficking and Golgi function, offer insights into how alterations in these cellular processes might influence ARL15's activity. Nitrendipine, a calcium channel blocker, and Dynasore, a dynamin inhibitor, represent a broader approach by targeting calcium-dependent signaling and vesicular trafficking, respectively.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Guanosine 5′-O-(3-thiotriphosphate) tetralithium salt | 94825-44-2 | sc-202639 | 10 mg | $456.00 | ||
A non-hydrolyzable GTP analog, potentially enhancing ARL15's GTPase activity by stabilizing the GTP-bound active form. | ||||||
Tipifarnib | 192185-72-1 | sc-364637 | 10 mg | $720.00 | ||
Inhibits farnesylation, a post-translational modification, potentially affecting ARL15's localization and function. | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $252.00 $495.00 | 9 | |
A cholesterol-lowering drug that may influence lipid metabolism pathways involving ARL15. | ||||||
GGTI 298 | 1217457-86-7 | sc-361184 sc-361184A | 1 mg 5 mg | $189.00 $822.00 | 2 | |
Prevents geranylgeranylation, potentially affecting ARL15's function in membrane association and signaling. | ||||||
Clofibrate | 637-07-0 | sc-200721 | 1 g | $32.00 | ||
A lipid-lowering agent, could enhance ARL15's activity in regulating lipid metabolism. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $28.00 $88.00 $332.00 | 12 | |
Another cholesterol-lowering statin, may influence ARL15's activity in lipid metabolism pathways. | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $30.00 $87.00 $132.00 $434.00 | 13 | |
Similar to other statins, could affect lipid metabolism, potentially enhancing ARL15's functional role. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Disrupts Golgi structure and function, potentially affecting ARL15's role in vesicle transport. | ||||||
Phenylarsine oxide | 637-03-6 | sc-3521 | 250 mg | $40.00 | 4 | |
Inhibits vesicular trafficking, potentially influencing ARL15's activity in this process. | ||||||
Nitrendipine | 39562-70-4 | sc-201466 sc-201466A sc-201466B | 50 mg 100 mg 500 mg | $107.00 $157.00 $449.00 | 6 | |
A calcium channel blocker, may indirectly affect ARL15's function in calcium-dependent signaling pathways. | ||||||